Emily L. Larkin

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation

Emily L. Larkin, Christopher Hager, Jyotsna Chandra et al. · Antimicrobial Agents and Chemotherapy · 2017 · 393 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Effectiveness of Disinfectants Against <i>Candida auris</i> and Other <i>Candida</i> Species

Jennifer L. Cadnum, Aaron Shaikh, Christina Piedrahita et al. · Infection Control and Hospital Epidemiology · 2017 · 205 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +13

<i>In Vitro</i> and <i>In Vivo</i> Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris

Christopher Hager, Emily L. Larkin, Lisa Long et al. · Antimicrobial Agents and Chemotherapy · 2018 · 140 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model

Christopher Hager, Emily L. Larkin, Lisa Long et al. · Journal of Antimicrobial Chemotherapy · 2018 · 98 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis

Mahmoud A. Ghannoum, L. Long, Emily L. Larkin et al. · Antimicrobial Agents and Chemotherapy · 2018 · 81 citations · Full text

Life Sciences, Microbiology, Pharmacology +17